2H-Pyrido[2,1-a]isoquinoline | 231-00-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 2H-Pyrido[2,1-a]isoquinoline
• 英文别名: 2H-benzo[a]quinolizine
• CAS: 231-00-5
• 化学式: C₁₃H₁₁N
• 分子量: 181.23
• InChiKey: NCFUIPADGNPPPP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  14
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• Pyrido [2,1-a] isoquinoline derivatives
  申请人：——

  公开号：US20040259903A1

  公开（公告）日：2004-12-23

  The present invention provides compounds of formula (I) 1 wherein R 1 , R 2 , R 3 and R 4 are as indicated in the description, or a pharmaceutically acceptable salt thereof. The compounds are useful for the treatment of diseases which are associated with DPP-IV, such as diabetes, particularly non-insulin dependent diabetes mellitus, and impaired glucose tolerance.

  本发明提供了式（I）的化合物，其中R1、R2、R3和R4如描述中所示，或其药学上可接受的盐。这些化合物可用于治疗与DPP-IV相关的疾病，如糖尿病，特别是非胰岛素依赖型糖尿病和糖耐量受损。
• [EN] [9,10-DIMETHOXY-3-(2-METHYLPROPYL)-1H,2H,3H,4H,6H,7H,11BH-PYRIDO-[2,1-A]ISOQUINOLIN-2-YL]METHANOL AND COMPOUNDS, COMPOSITIONS AND METHODS RELATING THERETO<br/>[FR] [9,10-DIMÉTHOXY-3-(2-MÉTHYLPROPYL)-1H,2H,3H,4H,6H,7H,11BH-PYRIDO-[2,1-A]ISOQUINÉLOIN-2-YL]MÉTHANOL ET COMPOSÉS, COMPOSITIONS ET PROCÉDÉS ASSOCIÉS
  申请人：NEUROCRINE BIOSCIENCES INC

  公开号：WO2016127133A1

  公开（公告）日：2016-08-11

  Compounds having a structure of formula (I), including stereoisomers and pharmaceutically acceptable salts and solvates thereof: wherein R1 is as defined herein. Such compounds are inhibitors of the vesicular monoamine transporter 2 (VMAT2) and have utility for treating, for example, hyperkinetic disorders. Also disclosed are compositions containing these compounds in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use in a subject in need thereof.

  具有化学式（I）结构的化合物，包括其立体异构体和药用可接受的盐和溶剂化合物：其中R1如本文所定义。这些化合物是囊泡单胺转运体2（VMAT2）的抑制剂，可用于治疗例如过动症等疾病。还披露了含有这些化合物的组合物和药用可接受载体的组合物，以及与使用在需要的受试者相关的方法。
• Substituted pyrido [2,1-a] isoquinoline derivatives
  申请人：Boehringer Markus

  公开号：US20060116393A1

  公开（公告）日：2006-06-01

  The present invention relates to compounds of formula (I) wherein R 1 to R 4 are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with DPP-IV, such as diabetes, particularly non-insulin dependent diabetes mellitus, and impaired glucose tolerance.

  本发明涉及式(I)的化合物，其中R1至R4如描述和索赔中定义，并且其药学上可接受的盐。这些化合物对与DPP-IV相关的疾病的治疗和/或预防有用，例如糖尿病，特别是非胰岛素依赖型糖尿病和糖耐量受损。
• PROCESS FOR THE PREPARATION OF PYRIDO[2,1-a] ISOQUINOLINE DERIVATIVES
  申请人：Abrecht Stefan

  公开号：US20090163718A1

  公开（公告）日：2009-06-25

  The present invention relates to a novel process for the preparation of pyrido[2,1-a]isoquinoline derivatives of the formula wherein R 2 , R 3 and R 4 are each independently selected from the group consisting of hydrogen, halogen, hydroxy, lower alkyl, lower alkoxy and lower alkenyl, wherein lower alkyl, lower alkoxy and lower alkenyl may optionally be substituted by a group consisting of lower alkoxycarbonyl, aryl and heterocyclyl, and the pharmaceutically acceptable salts thereof. The pyrido[2,1-a]isoquinoline derivatives of the formula I are useful for the treatment and/or prophylaxis of diseases which are associated with DPP IV.

  本发明涉及一种用于制备式中的吡啶[2,1-a]异喹啉衍生物的新型过程R2，R3和R4分别独立地选自由氢，卤素，羟基，较低烷基，较低烷氧基和较低烯基的群，其中较低烷基，较低烷氧基和较低烯基可以选择性地被较低烷氧羰基，芳基和杂环烷基的群取代，以及其药学上可接受的盐。式I的吡啶[2,1-a]异喹啉衍生物对与DPP IV相关的疾病的治疗和/或预防是有用的。
• PROCESS FOR THE PREPARATION OF PYRIDO &lsqb; 2-1-A&rsqb; ISOQUINOLINE DERIVATIVES BY CATALYTIC ASYMMETRIC HYDROGENATION OF AN ENAMINE
  申请人：Abrecht Stefan

  公开号：US20080076925A1

  公开（公告）日：2008-03-27

  The invention relates to a process for the preparation of pyrido[2,1- a ] isoquinoline derivatives of the formula wherein R 2 , R 3 and R 4 are as defined in the specification, comprising the steps of a) catalytic asymmetric hydrogenation of an enamine of the formula wherein R 1 is lower alkyl, in the presence of a transition metal catalyst containing a chiral diphosphane ligand, b) introduction of an amino protecting group Prot and c) amidation of the ester to form an amide of formula wherein R 2 , R 3 , R 4 and Prot are as defined in the specification.

  本发明涉及一种制备式为的吡啶并[2,1-a]异喹啉衍生物的方法，其中R2、R3和R4如规范中所定义，包括以下步骤：a）在手性二膦配体存在下，对式为的烯胺进行催化不对称氢化，其中R1为低碳基；b）引入氨基保护基Prot；c）酰胺化酯，形成式为的酰胺，其中R2、R3、R4和Prot如规范中所定义。